Key result
CABG cuts all-cause mortality ~25% vs. medical therapy alone in high-risk ischaemic cardiomyopathy.
Why the study?
To identify ischaemic cardiomyopathy patients with different phenotypes to evaluate their outcomes and heterogeneous treatment effects of CABG.
Does CABG reduce all-cause mortality in specific phenotypes of patients with ischaemic cardiomyopathy compared to medical therapy alone?
Cohort (n=1,212)
Open-label
1:1 randomization
Yes
Does CABG reduce all-cause mortality in specific phenotypes of patients with ischaemic cardiomyopathy compared to medical therapy alone?
Hazard Ratio: 0.75 (95% CI 0.58–0.96)
Absolute Event Rate: 71.3% vs 80.5%
p-value: p=0.025
Machine learning clustering identifies a high-risk phenotype of ischaemic cardiomyopathy (characterized by lower LVEF, higher NYHA class, and diabetes) that derives significant survival benefit from CABG.
Supports targeted CABG evaluation in this ML-identified high-risk phenotype; leaves open randomized confirmation before practice change.
Aims To identify ischaemic cardiomyopathy (ICM) patients with different phenotypes for evaluating their outcomes and heterogeneous treatment effects (HTEs) of coronary artery bypass grafting (CABG). Methods and results We applied a machine learning-based consensus, K-Medoids clustering analysis to the Surgical Treatment for Ischemic Heart Failure trial. We compared the risk of all-cause mortality and cardiovascular mortality among different phenotypes. The survival benefits of CABG compared with medical therapy alone were assessed in the identified phenotypes for evaluating HTEs. The consensus clustering analysis identified three distinct clinical phenotypes among 1212 ICM patients based on 19 variables. Specifically, phenotype 1 (n = 371) was characterized by younger ages, higher left ventricular ejection fraction (LVEF), and lower left ventricular end-systolic volume index (n = 371). Phenotype 2 had higher angina grades and more left main/left anterior descending artery stenosis (n = 520). Phenotype 3 had lower LVEF, higher New York Heart Association (NYHA) grades, more diabetes, and less hypertension (n = 321). After a median of 9.8 follow-up years, phenotype 3 had the highest risk of all-cause mortality [hazard ratio (HR), 1.96; 95% confidence intervals (CI), 1.62–2.37] and cardiovascular mortality (HR, 2.46; 95% CI, 1.95–3.10) compared to phenotype 1. Among phenotype 3, CABG provided significant survival benefits in all-cause mortality (HR, 0.75; 95% CI, 0.58–0.96) and cardiovascular mortality (HR, 0.67; 95% CI, 0.50–0.90) compared with medical therapy alone. Conclusion We identified three phenotypes with distinct outcomes and HTEs among ICM patients. Patients with lower LVEF, higher NYHA grades, and diabetes had the poorest clinical outcomes but were more likely to derive greater survival benefits from CABG.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2025) conducted a cohort in Ischaemic cardiomyopathy (n=1,212). Coronary artery bypass grafting (CABG) vs. Medical therapy alone was evaluated on All-cause mortality in high-risk phenotype 3 (HR 0.75, 95% CI 0.58-0.96, p=0.025). In patients with ischaemic cardiomyopathy and a high-risk phenotype (lower LVEF, higher NYHA grades, and diabetes), CABG significantly reduced all-cause mortality by 25% compared to medical therapy alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: